Using C-reactive protein (CRP), a non-specific marker of infections, or procalcitonin, a more specific marker of bacterial infections, to guide the decision of antibiotic treatment is not recommended for exacerbations of COPD [1]. The gene discussed is CRP; the disease is bacterial infectious disease.